Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Sofinnova Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
2,015,644Website Global Rank
8,743Website Monthly Traffic
Twitter Followers
Description
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs. It was headquartered in Paris, Ile-de-France in 1972.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2002 | EnvoyWorldWide | Series B | 8M |
| 3/2017 | HotSpot Therapeutics | Seed Round | - |
| 1/2003 | Varioptic | Series A | 2.1M |
| 2/2013 | Entourage Medical Technologies | Venture Round | 3.3M |
| 11/2020 | Myricx Pharma | Seed Round | 5.9M |
| 3/2019 | POLYNEURON | Series A | 22.6M |
| 12/2009 | Sensitive Object | Series B | 6M |
| 10/2021 | Sphere Fluidics | Venture Round | 41.4M |
| 11/2015 | ObsEva | Series B | 58.9M |
| 9/2019 | Inventiva Pharma | Post-IPO Equity | 681.2k |
| 4/2020 | Genespire | Series A | 17.4M |
| 11/2011 | NuCana | Series A | 0 |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 6/2008 | Creabilis | Series A | 31.4M |
| 11/2022 | Microphyt | Series B | 0 |
| 4/2005 | TAK imaging | Series C | 10M |
| 9/2006 | Oxxius | Series B | 10M |
| 6/2005 | Endotis | Series A | 4.9M |
| 5/2014 | Odoo | Series B | 10M |
| 9/2004 | Oxxius | Series A | 2.9M |
| 5/2005 | Sefas Innovation | Venture Round | 3.8M |
| 1/2022 | SafeHeal | Venture Round | 0 |
| 9/2016 | Delinia | Series A | 35M |
| 8/2008 | mydeco | Series A | 14.5M |
| 10/2006 | Wyplay | Series A | 5.1M |
| 6/2007 | PregLem | Series A | 26M |
| 3/2016 | TISSIUM | Series A | 25.5M |
| 2/2020 | Inventiva Pharma | Post-IPO Equity | 16.4M |
| 7/2010 | Mainstay Medical | Series A | 6.1M |
| 6/2019 | AFYX Therapeutics | Debt Financing | 13M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 11/2016 | Corwave | Series B | 17.1M |
| 4/2020 | Epsilen Bio | Seed Round | - |
| 7/2007 | Diatos | Series D | 12.8M |
| 11/2021 | Home Biosciences | Seed | 15M |
| 5/2020 | PinCell s.r.l. | Seed Round | 1.6M |
| 12/2007 | PregLem | Series B | 32.2M |
| 4/2022 | Prometheus Materials | Series A | 8M |
| 8/2021 | TISSIUM | Series C | 59.1M |
| 4/2020 | EnginZyme | Series A | 6.9M |
| 7/2019 | Abivax | Post-IPO Equity | 13.5M |
| 10/2002 | Cobion | Venture Round | 5.9M |
| 3/2010 | Omthera Pharmaceuticals | Series A | 6.5M |
| 4/2013 | MedDay | Series A | 10.5M |
| 1/2016 | ENYO Pharma | Series A | 23.9M |
| 8/2006 | Ablynx | Series C | 50M |
| 8/2000 | BioSpace | Series B | 10M |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 12/2019 | GenSight Biologics | Post-IPO Debt | 16.6M |
| 9/2010 | Bee Ware | Series B | 5.6M |
| 4/2022 | LimFlow SA | Series D | 0 |
| 5/2005 | Bee Ware | Series A | 3.8M |
| 3/2008 | Filao | Venture Round | 0 |
| 3/2005 | Sequoia Pharmaceuticals | Series B | 22M |
| 12/2007 | Ascendis Pharma | Series A | 25.7M |
| 7/2020 | Enthera | Series A | 0 |
| 3/2005 | Filao | Venture Round | 4.6M |
| 4/2014 | ProQR Therapeutics | Series A | 57.9M |
| 3/2018 | SafeHeal | Series A | 7.4M |
| 3/2016 | CelluComp | Venture Round | 5.3M |
| 1/2006 | Blyk | Series A | 35.4M |
| 1/2007 | Stentys | Seed Round | - |
| 11/2021 | Synthace | Series C | 35M |
| 7/2020 | MISSION Therapeutics | Venture Round | 15M |
| 1/2010 | BioAmber | Series A | 0 |
| 10/2022 | Mablink Bioscience | Series A | 30.1M |
| 9/2013 | Synthace | Seed Round | 2.1M |
| 5/2009 | MXP4 | Series B | 2.7M |
| 7/2021 | protera | Series A | 0 |
| 5/2004 | Addex Therapeutics | Series B | 0 |
| 3/2007 | MXP4 | Series A | 6.5M |
| 3/2009 | Neosens | Series B | 5.3M |
| 2/2008 | Neosens | Venture Round | 3.7M |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 1/2004 | Infra Worlds | Series A | 1.7M |
| 11/2013 | Pixium Vision | Series A | 20.3M |
| 2/2019 | GenSight Biologics | Post-IPO Equity | 9.1M |
| 5/2023 | BrightHeart | Seed Round | 2.1M |
| 9/2022 | Abivax | Post-IPO Equity | 0 |
| 1/2008 | CrestaTech | Series A | 5M |
| 4/2020 | RefleXion Medical | Series D | 0 |
| 7/2009 | EOS (Ethical Oncology Science) | Series A | 17M |
| 1/2005 | CrestaTech | Seed Round | 1.5M |
| 2/2003 | Avaki | Series A | 4.2M |
| 1/2009 | DBV Technologies | Series B | 7.8M |
| 1/2006 | DBV Technologies | Venture Round | 15.1M |
| 1/2013 | ProQR Therapeutics | Seed Round | - |
| 10/2011 | Hookipa Pharma | Series A | 9.6M |
| 3/2018 | Micropep Technologies | Series A | 5M |
| 3/2008 | Laszlo Systems | Series C | 14.6M |
| 4/2006 | Endoart | Series C | 0 |
| 4/2016 | MedDay | Series B | 0 |
| 12/2022 | EnginZyme | Series B | 22.3M |
| 11/2011 | NuCana BioMed | Series A | 10.5M |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 10/2000 | Ingenium Pharmaceuticals AG | Series B | 44M |
| 12/2021 | DMC Biotechnologies | Series B | 0 |
| 12/2019 | DMC Biotechnologies | Series A | 0 |
| 12/2018 | Shockwave Medical | Series D | 0 |
| 5/2022 | GFBiochemicals | Series A | 0 |
| 7/2019 | AblaCare | Series A | 11.2M |
| 2/2017 | Zyl | Venture Round | - |
| 3/2017 | Biotalys | Series B | 0 |
| 12/2013 | Crescendo Biologics | Series A | 28.5M |
| 1/2002 | Innate Pharma | Series B | 17.8M |
| 4/2004 | Ablynx | Series B | 30M |
| 7/2007 | Inside Secure | Series B | 0 |
| 3/2000 | Innate Pharma | Series A | 4.4M |
| 3/2023 | Noema Pharma | Series B | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 12/2013 | Green Biologics | Series B | 0 |
| 2/2008 | Ocera Therapeutics | Series C | 0 |
| 12/2007 | Fovea Pharmaceuticals | Series B | 30M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 7/2006 | Accent | Venture Round | 13.3M |
| 5/2019 | DNA Script | Series B | 38.5M |
| 1/2009 | Revolt Technology | Series B | 13.1M |
| 10/2006 | Domain Therapeutics | Series C | 10.4M |
| 11/2003 | Esmertec AG | Series C | 0 |
| 6/2021 | Borea Therapeutics | Seed Round | - |
| 6/2005 | Revolt Technology | Series A | 8.5M |
| 5/2015 | Twenga | Series A | 11M |
| 10/1998 | BoostWorks | Series A | 3M |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 1/2005 | VoluBill | Series C | 0 |
| 1/2004 | Intransa | Series C | 8M |
| 4/2008 | Qosmos | Series C | 10.8M |
| 11/2021 | GlycoEra | Series A | 0 |
| 9/2019 | Inotrem | Series B | 43.1M |
| 2/2002 | Tak Imaging | Series B | 9.5M |
| 5/2010 | Crocus Technology | Series C | 0 |
| 10/2004 | Sensitive Object | Series A | 2.5M |
| 4/2018 | LimFlow SA | Series C | 33.4M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 7/2021 | protera | Series A | 0 |
| 8/2022 | F2G | Private Equity Round | 0 |
| 7/2005 | Filao | Venture Round | 0 |
| 7/2007 | GlycoVaxyn | Series A | 9.5M |
| 6/2019 | Comet Therapeutics | Series A | 28.5M |
| 9/2007 | Purple Labs | Series A | 12.7M |
| 4/2002 | Esmertec AG | Venture Round | 8.8M |
| 4/2013 | Aledia | Series A | 12.8M |
| 11/2002 | PhyFlex Networks | Series B | 0 |
| 1/2019 | HighLife | Series B | 36M |
| 6/2010 | QuesCom | Venture Round | 0 |
| 7/2021 | Micropep Technologies | Series A | 10.1M |
| 6/2022 | Micropep Technologies | Series A | 0 |
| 2/2002 | Domain Therapeutics | Series A | 2.6M |
| 7/2019 | Biotalys | Series C | 0 |
| 10/2010 | ASSIA | Series D | 20.8M |
| 1/2007 | Movetis | Series A | 63.8M |
| 10/2018 | Sitryx Therapeutics | Series A | 30M |
| 4/2020 | Pi-Cardia | Venture Round | 27M |
| 7/2020 | Pixium Vision | Post-IPO Equity | 8.3M |
| 1/2003 | Intransa | Series B | 6M |
| 7/2002 | Addex Therapeutics | Series A | 9.9M |
| 9/2002 | Ablynx | Series A | 4.9M |
| 9/2017 | Synthace | Series A | 9.9M |
| 9/2017 | DNA Script | Series A | 13.2M |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 5/2020 | HotSpot Therapeutics | Series B | 65M |
| 3/2004 | UPEK | Series A | 20M |
| 3/2020 | Redx Pharma | Post-IPO Equity | 33.6M |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 4/2005 | Tak Imaging | Series C | 10M |
| 11/2005 | Fovea Pharmaceuticals | Series A | 24.2M |
| 1/2004 | Tak Imaging | Series C | 16.3M |
| 7/1999 | BoostWorks | Series B | 7M |
| 2/2013 | MetGen | Venture Round | 2.9M |
| 12/2007 | Streamezzo | Series C | 22M |
| 8/2004 | Intransa | Series D | 24M |
| 11/2006 | Abionyx Pharma | Series B | 53.5M |
| 6/2020 | Protera | Series A | 5.6M |
| 3/2008 | Mobile Digital Media | Venture Round | 0 |
| 7/2019 | Comet Biorefining | Venture Round | - |
| 1/2015 | Green Biologics | Equity | 42M |
| 2/2002 | Intransa | Venture Round | 10M |
| 4/2018 | Inventiva Pharma | Post-IPO Equity | 44.4M |
| 2/2015 | Synthace | Venture Round | 3.4M |
| 11/2006 | CoreValve | Venture Round | 20M |
| 7/2006 | GlycoVaxyn | Seed Round | - |
| 10/2009 | Crescendo Biologics | Seed Round | 0 |
| 5/2004 | Domain Therapeutics | Series B | 19.1M |
| 1/2018 | Aledia | Series C | 0 |
| 1/2005 | Biolipox | Series C | 41M |
| 5/2010 | Noxxon Pharma | Series D | 40.7M |
| 5/2014 | Avantium | Series G | 0 |
| 2/2016 | MISSION Therapeutics | Series C | 86.5M |
| 5/2007 | Noxxon Pharma | Series C | 50.2M |
| 3/2014 | Inotrem | Series A | 25.1M |
| 11/2018 | InCarda Therapeutics | Series B | 42M |
| 4/2018 | Erydel | Series B | 32.4M |
| 9/2020 | POLYNEURON | Series A | 15.4M |
| 4/2014 | Crescendo Biologics | Series A | 3.3M |
| 4/2014 | RefleXion Medical | Series A | 11.6M |
| 11/2014 | myTomorrows | Venture Round | 5.6M |
| 10/2020 | GenSight Biologics | Post-IPO Equity | 0 |
| 2/2012 | BioAmber | Series C | 0 |
| 10/2017 | HighLife | Series A | 14.3M |
| 7/2018 | HotSpot Therapeutics | Series A | 45M |
| 3/2009 | GlycoVaxyn | Series B | 21.4M |
| 5/2018 | Biosyntia | Series A | 4.7M |
| 10/2011 | Creabilis | Series B | 20M |
| 4/2015 | ReCor Medical | Series D | 15M |
| 11/2019 | TISSIUM | Series B | 43.2M |
| 4/2006 | Varioptic | Series C | 0 |
| 6/2015 | Aledia | Series B | 0 |
| 7/2019 | Microphyt | Venture Round | 31.9M |
| 6/2018 | Castle Biosciences | Venture Round | 0 |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 6/2009 | blueKiwi software | Series B | 0 |
| 1/2008 | TAK imaging | Series C | 16.2M |
| 9/2002 | EnvoyWorldWide | Series C | 4.5M |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 2/2018 | Mainstay Medical | Post-IPO Equity | 37.5M |
| 2/2021 | Mainstay Medical | Private Equity Round | 0 |
| 6/2018 | NodThera | Series A | 40M |
| 6/2016 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series B | 33M |
| 1/2003 | Biolipox | Series B | 21M |
| 12/2021 | EndoRon Medical | Seed Round | 5M |
| 9/2006 | Addex Therapeutics | Series C | 0 |
| 3/2008 | Stentys | Series A | 18M |
| 1/2007 | blueKiwi software | Series A | 5.3M |
| 2/2019 | AFYREN | Venture Round | 23.8M |
| 10/2021 | Leucid Bio | Series A | 15.9M |
| 7/2022 | Biosyntia | Series B | 11.7M |
| 1/2011 | DBV Technologies | Series C | 25.5M |
| 4/2014 | NuCana | Series B | 0 |
| 5/2019 | CinCor Pharma | Series A | 50M |
| 3/2004 | Varioptic | Series B | 12.2M |
| 3/2017 | Comet Biorefining | Venture Round | - |
| 4/2018 | EnobraQ | Seed Round | 3.6M |
| 7/2021 | Comet Biorefining | Series C | 0 |
| 7/2010 | Abionyx Pharma | Series C | 0 |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2016 | MD Start | Venture Round | 0 |
| 10/2003 | Cotherix | Series C | 55M |
| 9/2004 | Innate Pharma | Series C | 0 |
| 5/2009 | Streamezzo | Series D | 5.5M |
| 4/2016 | RefleXion Medical | Series B | 52M |
| 4/2018 | RefleXion Medical | Series C | 100M |
| 2/2016 | Corvidia | Series A | 26M |
| 1/2007 | Sequoia Pharmaceuticals | Series C | 35M |
| 4/2006 | Streamezzo | Series B | 0 |
| 11/2016 | Shockwave Medical | Series C | 45M |
| 6/2021 | Alia Therapeutics | Seed Round | - |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 6/2013 | MetGen | Series A | - |
| 5/2015 | Shockwave Medical | Series B | 40M |
| 6/2016 | DNA Script | Seed Round | 2.8M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 3/2007 | CoreValve | Series C | 33M |
| 8/2005 | Abionyx Pharma | Series A | 30.5M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 11/2020 | Catamaran Bio | Series A | 0 |
| 12/2020 | Noema Pharma | Series A | 60M |
| 1/2017 | myTomorrows | Venture Round | 10.6M |
| 2/2006 | Lectus Therapeutics | Series A | 14.3M |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 4/2005 | Laszlo Systems | Series B | 6.3M |
| 9/2007 | VoluBill | Series D | 0 |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 1/2008 | Inside Secure | Series C | 0 |
| 3/2011 | Omthera Pharmaceuticals | Series B | 33.9M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 6/2020 | NodThera | Series B | 55M |
| 3/2017 | Breath Therapeutics | Series A | 45.9M |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 10/2021 | IOmx Therapeutics | Series B | 0 |
| 4/2018 | Corvidia | Series B | 60M |
| 5/2020 | CorVent Medical | Seed Round | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 2/2010 | Odoo | Series A | 4.1M |
| 11/2013 | MISSION Therapeutics | Series B | 32.2M |
| 8/2011 | MISSION Therapeutics | Series A | 6M |
| 9/2006 | Qosmos | Series B | 4.1M |
| 4/2020 | Pyrowave | Series B | - |
| 1/2021 | Corwave | Series C | 43.2M |
| 7/2018 | Enthera | Seed Round | 4.7M |
| 11/2013 | CelluComp | Seed Round | 3.9M |
| 2/2022 | Elicit Plant | Series A | 18.3M |
| 1/2014 | Shockwave Medical | Series A | 12.5M |
| 6/2021 | AAVantgarde Bio | Seed Round | - |
| 4/2013 | Auris Medical | Series C | 51M |
| 6/2022 | Moon Surgical | Series A | 31.3M |
| 2/2015 | Comet Biorefining | Venture Round | - |
| 5/2023 | BrightHeart | Seed Round | 0 |
| 5/2023 | TISSIUM | Series D | 0 |
| 5/2023 | Moon Surgical | Series B | 0 |
| 5/2023 | Werewool | Seed Round | 0 |
| 4/2023 | Alia Therapeutics | Seed Round | 0 |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 3/2023 | deepc | Series A | 0 |
| 3/2023 | Kiro | Series A | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
